/HKMPF

HKMPF Stock - Hikma Pharmaceuticals PLC

Q: What is the analyst price target for HKMPF?

Analyst price target information is not currently available for HKMPF.

Q: What is HKMPF's market cap?

Market capitalization information is not currently available for HKMPF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$19.98-2.05%

$0.42 (-2.05%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $21.98

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HKMPF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.71

52W High$28.91

52W Low$19.98

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$3.13B	$2.88B	$2.52B	$2.55B	$2.34B
Gross Profit	$1.42B	$1.41B	$1.26B	$1.30B	$1.21B
Gross Margin	45.3%	48.9%	50.3%	51.0%	51.8%
Operating Income	$612.00M	$367.00M	$282.00M	$582.00M	$579.00M
Net Income	$359.00M	$190.00M	$188.00M	$421.00M	$431.00M
Net Margin	11.5%	6.6%	7.5%	16.5%	18.4%
EPS	$1.62	$0.85	$0.84	$1.82	$1.83

Company Overview

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish2 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 7th 2023	Jefferies	Downgrade	Hold	-
September 6th 2023	RBC Capital Mkts	Downgrade	Sector Perform	-
December 6th 2022	RBC Capital Mkts	Initiation	Outperform	-
November 15th 2022	Credit Suisse	Initiation	Outperform	-
May 25th 2022	JP Morgan	Downgrade	Neutral	-

Earnings History & Surprises

HKMPF

Beat Rate

40%

Last 10 quarters

Avg Surprise

-13.2%

EPS vs Estimate

Beats / Misses

4/6

Last 12 quarters

Latest EPS

$1.07

Q3 2025

EPS Surprise History

Q4 21

-24.5%

$0.73vs$0.97

Q2 22

-23.4%

$0.71vs$0.93

Q4 22

-91.0%

$0.07vs$0.78

Q2 23

-36.1%

$0.61vs$0.95

Q2 24

-72.0%

$0.27vs$0.96

Q3 24

No data

Q1 25

No data

Q3 25

-12.3%

$1.07vs$1.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 24, 2026	—	—	—	—
Q3 2025	Aug 7, 2025	$1.22	$1.07	-12.3%	✗ MISS
Q1 2025	Feb 26, 2025	—	$0.60	—	—
Q3 2024	Aug 8, 2024	—	$1.01	—	—
Q2 2024	Apr 25, 2024	$0.96	$0.27	-72.0%	✗ MISS
Q2 2023	Jun 30, 2023	$0.95	$0.61	-36.1%	✗ MISS
Q4 2022	Dec 31, 2022	$0.78	$0.07	-91.0%	✗ MISS
Q2 2022	Jun 30, 2022	$0.93	$0.71	-23.4%	✗ MISS
Q4 2021	Dec 31, 2021	$0.97	$0.73	-24.5%	✗ MISS
Q2 2021	Jun 30, 2021	$0.90	$1.06	+17.8%	✓ BEAT
Q4 2020	Dec 31, 2020	$0.87	$0.98	+13.0%	✓ BEAT
Q2 2020	Jun 30, 2020	$0.74	$0.86	+15.7%	✓ BEAT
Q4 2019	Dec 31, 2019	$0.72	$1.30	+80.6%	✓ BEAT
Q2 2019	Jun 30, 2019	—	$0.75	—	—
Q4 2018	Dec 31, 2018	—	$0.73	—	—
Q2 2018	Jun 30, 2018	—	$0.44	—	—
Q4 2017	Dec 31, 2017	—	$-3.80	—	—
Q2 2017	Jun 30, 2017	—	$0.29	—	—
Q4 2016	Dec 31, 2016	—	$0.40	—	—
Q2 2016	Jun 30, 2016	—	$0.25	—	—

Frequently Asked Questions about HKMPF

What is HKMPF's current stock price?

Hikma Pharmaceuticals PLC (HKMPF) is currently trading at $19.98 per share. The stock has moved -2.05% today.

What is the analyst price target for HKMPF?

No analyst price targets are currently available for this stock.

What sector is Hikma Pharmaceuticals PLC in?

Hikma Pharmaceuticals PLC operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is HKMPF's market cap?

Hikma Pharmaceuticals PLC has a market capitalization of $4.41 billion, making it a mid-cap company.

Does HKMPF pay dividends?

No, Hikma Pharmaceuticals PLC does not currently pay a dividend to shareholders.